Premier Alternatives

ArsenalBio

South San Francisco, CA · Founded 2018 · Privately Held (backing)

Operator of a programmable cell therapy company intended to discover, develop, and commercialize curative immune cell therapies. ArsenalBio is based in South San Francisco, CA and was founded in 2018. Its last known valuation is $1.9 billion. It has raised $631 million.

Last price · $/share
—
Implied valuation
$1.9B
Total raised
$630.8M
Last round
—

ArsenalBio key facts

  • Operator of a programmable cell therapy company intended to discover, develop, and commercialize curative immune cell therapies.
  • ArsenalBio’s last known valuation is $1.9B.
  • It has raised $630.8M; the latest was Later Stage VC ($325.0M) in Sep 2024.
  • Notable investors include SoftBank Investment Advisers, Kleiner Perkins, University of California, ARCH Venture Partners, Emerson Collective — 24 tracked in total.
  • Status: Privately Held (backing).
Free account
More of ArsenalBio with a free account
  • ·The complete investor list: 24 names
  • ·Watch ArsenalBio: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

ArsenalBio funding rounds

No rounds on record

No funding rounds for ArsenalBio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

ArsenalBio valuation

ArsenalBio's last known valuation is $1.9 billion. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.

ArsenalBio investors

24 investors are on record for ArsenalBio, including SoftBank Investment Advisers, Kleiner Perkins, University of California and ARCH Venture Partners. By type, the record holds 4 venture capital firms and 2 family offices.

About ArsenalBio

Operator of a programmable cell therapy company intended to discover, develop, and commercialize curative immune cell therapies. The company offers a full-stack research and development engine that generates multifunctional T-cell medicines, enabled by the specific insertion of large synthetic deoxyribonucleic acid sequences, enabling clinicians with next-generation autologous T-cell therapies to defeat cancer.

Sector
Healthcare
HQ
South San Francisco, CA, United States
Founded
2018
Employees
289
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.

Valuation on record
$1.9B

ArsenalBio’s last known valuation. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.